Back to top
more

Moderna (MRNA)

(Real Time Quote from BATS)

$123.22 USD

123.22
1,862,054

-1.92 (-1.53%)

Updated Jul 17, 2024 03:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Moderna (MRNA) to Supply Omicron-based COVID Jab in Canada

by Zacks Equity Research

Moderna's (MRNA) Omicron-specific bivalent vaccine booster is yet to be approved by Canadian health authorities. The government seeks to purchase 12 million doses of the same in 2022.

Pfizer (PFE), BioNTech Seek FDA Nod for Omicron Variant Booster

by Zacks Equity Research

Pfizer (PFE) and BioNTech's (BNTX) Omicron BA.4/BA.5-adapted bivalent vaccine contains mRNA encoding the spike protein present in the original vaccine as well as mRNA encoding the spike protein of the Omicron BA.4/BA.5 variant.

Novavax (NVAX) COVID-19 Vaccine Gets FDA Nod for Adolescents

by Zacks Equity Research

Post the label expansion by the FDA, Novavax's (NVAX) COVID-19 vaccine is the first protein-based COVID vaccine authorized for use in individuals aged 12 years and older in the United States.

Vertex (VRTX) Stock Up 36% This Year So Far: What Lies Ahead?

by Zacks Equity Research

Vertex's (VRTX) CF sales rise 22% in the first half of 2022, primarily driven by higher sales of Trikafta. Programs in five disease areas are now entering or progressing through late-stage clinical development.

Biotech Stock Roundup: GILD's Drug News, NVAX & MRNA COVID-19 Vaccine Updates

by Zacks Equity Research

Regulatory and pipeline updates from Gilead (GILD) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.

DENTSPLY SIRONA (XRAY) Falls After Nasdaq's Delinquency Notice

by Zacks Equity Research

The Nasdaq exchange issues a notice to DENTSPLY SIRONA (XRAY) for filing delinquency from the exchange and for non-compliance with the Nasdaq Listing Rules. Shares fall.

Novavax (NVAX) Seeks FDA Authorization for COVID-19 Booster Dose

by Zacks Equity Research

Novavax (NVAX) seeks label expansion from the FDA for its COVID-19 vaccine as a booster dose in adults. The vaccine is authorized as a primary two-dose regimen in adults.

Novavax's (NVAX) COVID Vaccine Aids Growth, Overdependence Ails

by Zacks Equity Research

Currently, Novavax (NVAX) has only one marketed product in its portfolio, its protein-based COVID-19 vaccine. However, it is lagging in competition behind mRNA-based vaccines.

Should Direxion NASDAQ100 Equal Weighted Index Shares (QQQE) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for QQQE

Novavax (NVAX) Q2 Earnings Miss, Cuts '22 Sales Guidance by Half

by Zacks Equity Research

Novavax (NVAX) reports dismal results in second-quarter 2022. The stock dives in after-market trading after management slashes revenue guidance for 2022 by half.

MRNA vs. TECH: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

MRNA vs. TECH: Which Stock Is the Better Value Option?

Company News for Aug 4, 2022

by Zacks Equity Research

Companies in The News Are: MRNA, REGN, HZNP, EXC

Moderna (MRNA) Beats on Q2 Earnings, Starts $3B Buyback Program

by Zacks Equity Research

Moderna's (MRNA) earnings and sales beat expectations. The company also announces another $3-billion buyback program. Stock gains in pre-market.

U.S. Stock Futures Rise on Strong Q2 Earnings

by Zacks Equity Research

Stock futures have risen in today¿¿¿s pre-market after two consecutive days of loss making.

Pre-markets Green on Strong Earnings Numbers

by Zacks Equity Research

Pre-markets Green on Strong Earnings Numbers.

Moderna (MRNA) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Moderna (MRNA) delivered earnings and revenue surprises of 16.44% and 22.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Moderna (MRNA) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the second-quarter earnings call that can lower its dependence on Spikevax.

Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Moderna (MRNA) Q2 Earnings Expected to Decline

by Zacks Equity Research

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $165.69, marking a +1.33% move from the previous day.

Here is What to Know Beyond Why Moderna, Inc. (MRNA) is a Trending Stock

by Zacks Equity Research

Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed the most recent trading day at $166.89, moving -0.15% from the previous trading session.

Novavax (NVAX) Up as CDC Endorses COVID Jab for Use in Adults

by Zacks Equity Research

Following the endorsement by the U.S. CDC, Novavax (NVAX) can now start immunizations with its COVID-19 vaccine as a primary two-dose regimen for use in adults in the United States.

Pfizer (PFE), BioNTech Seek EU Nod for Omicron-Based COVID Jab

by Zacks Equity Research

Pfizer (PFE) and BioNTech (BNTX) complete a regulatory filing for their Omicron-specific bivalent COVID-19 vaccine in the EU. The bivalent vaccine has been developed to target the Omicron BA.1 subvariant.

Moderna's (MRNA) COVID Jab Gets Nod For Kids in Canada

by Zacks Equity Research

Moderna's (MRNA) mRNA-based COVID-19 jab, SpikeVax, receives approval from Health Canada for children aged six months through five years.